Foghorn Therapeutics
FHTX
Market cap $428M

7.74 USD

-0.37

4.56%

At close Oct 17, 4:00 PM EDT

After hours

7.72

-0.02

0.26%

1 day

-4.56%

5 days

9.79%

1 month

-21.34%

3 months

21.51%

6 months

33.91%

Year to date

20.00%

1 year

116.20%

5 years

-57.28%

About: Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Employees: 116

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

240% more call options, than puts

Call options by funds: $34K | Put options by funds: $10K

44% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 16

27% more capital invested

Capital invested by funds: $178M [Q1] → $227M (+$48.9M) [Q2]

23% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 13

8.96% more ownership

Funds ownership: 62.33% [Q1] → 71.29% (+8.96%) [Q2]

4% more funds holding

Funds holding: 69 [Q1] → 72 (+3) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$9

16%

upside

Avg. target

$16

107%

upside

High target

$20

158%

upside

5 analyst ratings

4 positive

80%

1 neutral

20%

0 negative

0%

Morgan Stanley Vikram Purohit 67% 1-year accuracy 4 / 6 met price target	16%upside $9	Equal-Weight Maintained	24 Sept 2024
Jefferies Kelly Shi 44% 1-year accuracy 4 / 9 met price target	133%upside $18	Buy Initiated	3 Sept 2024
Evercore ISI Group Gavin Clark-Gartner 44% 1-year accuracy 4 / 9 met price target	158%upside $20	Outperform Initiated	19 Aug 2024
HC Wainwright & Co. Andrew Fein 48% 1-year accuracy 71 / 149 met price target	158%upside $20	Buy Reiterated	12 Aug 2024
Wedbush Robert Driscoll 44% 1-year accuracy 26 / 59 met price target	68%upside $13	Outperform Reiterated	9 Aug 2024

See Analyst Rankings

Financial journalist opinion

Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors

Primary target patient population for the FHD-909 Phase 1 trial is non-small cell lung cancer (NSCLC) Lilly leads the clinical development of the Phase 1 trial Foghorn's selective SMARCA2 oncology program is part of a U.S. 50/50 co-development and co-commercialization collaboration with Lilly CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- October 10, 2024 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that the first patient has been dosed with FHD-909 (LY4050784) in the Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target patient population.

Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors

Foghorn Therapeutics to Participate in the BMO Oncology Summit

CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in investor meetings at the BMO Oncology Summit being held Tuesday, October 8, 2024, in New York, NY. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Foghorn Therapeutics to Participate in the BMO Oncology Summit

Zacks Investment Research

Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength?

Foghorn Therapeutics (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength?

Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer

CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Anna Rivkin, Ph.D., will join the company as Chief Business Officer (CBO), on September 3, 2024. Dr. Rivkin brings over two decades of expertise in a broad spectrum of complex business transactions across multiple disease areas.

Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer

Zacks Investment Research

Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 81.16%: Read This Before Placing a Bet

The consensus price target hints at an 81.2% upside potential for Foghorn Therapeutics (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 81.16%: Read This Before Placing a Bet

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the 2024 Wells Fargo Healthcare Conference and presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September

Zacks Investment Research

Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 121.77%: Here's is How to Trade

The consensus price target hints at a 121.8% upside potential for Foghorn Therapeutics (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 121.77%: Here's is How to Trade

Zacks Investment Research

5 Small Drug Stocks to Buy as Innovation Reaches Peak

Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.

5 Small Drug Stocks to Buy as Innovation Reaches Peak

Zacks Investment Research

Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Tops Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.70 per share a year ago.

Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Tops Revenue Estimates

Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update

Topline Phase 1 dose escalation data for FHD-286 in combination with decitabine, in relapsed and/or refractory AML patients, anticipated in the fourth quarter of 2024

Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update

See News Rankings

Charts implemented using Lightweight Charts™